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To clarify the role of CD8+ eﬀector T cells for infectious complications, 92 recipients were classiﬁed according to the hierarchical
clustering of preoperative CD8+CD45 isoforms: Group I was naive, Group II was eﬀector memory, and Group III was eﬀector (E)
T cell-dominant. The posttransplant infection rates progressively increased from 29% in Group I to 64.3% in Group III recipients.
The posttransplant immune status was compared with the pretransplant status, based on the measure (% diﬀerence) and its
graphical form (scatter plot). In Groups I and II, both approaches showed a strong upward deviation from pretransplant status
upon posttransplant infection, indicating an enhanced clearance of pathogens. In Group III, in contrast, both approaches showed
a clear downward deviation from preoperative status, indicating deﬁcient cytotoxicity. The % E diﬀerence and scatter plot can be
used as a useful indicator of a posttransplant infectious complication.
Copyright © 2008 Shinji Uemoto et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Pre-existing high numbers of memory CD8+ Tc e l l sr e p -
resent a potent barrier for tolerance induction and aﬀect
the course of infection [1, 2]. Our previous ﬁndings accord
this, since recipients with pre-existing enriched eﬀector T
cells (subset CD45RO−CCR7−) had a high incidence of
posttransplant infection and poor survival probability [3].
We, therefore, examined whether qualitative changes in
CD8+ eﬀector T cell responses to viral or bacterial antigens
could explain why these pathogens are not eliminated in
most recipients with pre-existing high numbers of eﬀector T
cells. Indeed, posttransplant immune status remarkably dif-
fers among heterogeneous recipients, particularly at various
times after transplantation. Posttransplant immune allore-
active responses are highly complicated by immunosuppres-
sion, rejection, and infection. Although the role of immuno-
suppressivedrugsistoinhibitthealloimmuneresponse,they
render transplanted recipients highly immunodeﬁcient and
susceptible to bacterial and viral infections. Accordingly, we
are interested in how the cytotoxic T cell generation changes
in response to posttransplant infection after administration
of immunosuppressive drugs in heterogeneous recipients.
The reduction of immunosuppression is a major objec-
tive for every transplanted recipient in order to reduce drug
side eﬀectsand restore immunity against common infectious
agents. Several strategies show promise, and the predictive
values of helper [4], and cytotoxic precursor frequencies
[5, 6] in determining graft outcome. Measurements of
cytotoxic precursor frequencies have been used for immune
monitoring in an attempt to identify recipients suitable for
immunosuppression tapering [7] or withdrawal [8]. Other2 Clinical and Developmental Immunology
approaches such as “trans vivo” assays [9, 10], interferon-
gamma (IFN-γ)[ 11]o rI L - 2[ 12] secretion assays have
also been applied. Major histocompatibility complex class I
tetramer technology has recently proved clinically useful in
the monitoring of immunity to infectious diseases caused
by diﬀerent viruses. However, the use of human leukocyte
antigens(HLA)tetramerin atransplantsetting isinadequate
since it is routinely available only for a limited number
of recipients due to the heterogeneity of allopeptides and
allogenic HLA molecules. Our study aims to clarify the
phenotypic and functional changes in the CD8+ subpopu-
lation in many recipients with or without viral infection. We,
therefore, used phenotypic analyses for CD8+ and CD4+ T
cells to classify them into eﬀector, eﬀector memory (EM),
central memory (CM), and naive cells. We believe that
conventionalmethodsofthissortarefullyadequatetofollow
up the clinical outcome in a longitudinal study and to make
inferences regarding the clinical situation.
A number of above and other assay [13, 14] are presently
being evaluated for eﬃcacy in posttransplant immune mon-
itoring. However, the time-consuming assays with labor-
intensiveness or the expensive cost-consuming nature of
these assays have prevented their broad acceptance as reliable
immune monitoring tools. Since posttransplant infectious
complicationsarethegreatestfactorleadingtoseriouslypoor
outcomes, we need simple and eﬀective assays of current
immune status for predicting such complications that can be
applied to a large cohort of transplanted recipients.
We postulated that immune ability would always recover
to preoperative levels, even though it is transiently down-
regulated in the early postoperative period. Hence, we
investigated how posttransplant immune status evaluated
by circulating eﬀe c t o rTc e l l sd e v i a t e sf r o mp r e t r a n s p l a n t
statusatvarioustimesafterlivingdonorlivertransplantation
(LDLT) and leads to severe infectious complications.
2. PATIENTS AND METHODS
2.1. Patientsandgrafts
We examined 92 recipients who had undergone standard
LDLT between 2002 and 2006 at Kyoto University Hospital.
The ABO incompatible recipients were excluded from this
study. Written informed consent was obtained from the
recipients before starting the study, which was approved
by the Ethics Committee of Kyoto University Hospital and
conducted in accordance with the 1975 Declaration of
Helsinki, as revised in 1996.
2.2. Immunosuppression
Methylprednisolone (initial steroid bolus, ISB; 10mg/kg)
was administered just prior to the start of graft reperfusion.
Afterward, two types of immunosuppression protocol in
this study were routinely applied: (1) a regular protocol
using tacrolimus (Tac) and corticosteroid; and (2) steroid-
free protocol using Tac and mycophenolate mofetil instead
of corticosteroid for hepatitis C virus (HCV) patients.
The regular protocol was followed in 85 (92.4%) of 92
recipients, and the steroid-free protocol in the remaining 7
(7.6%) HCV-infected recipients. The recipients receiving the
steroid-free protocol comprised 3 in Group I, 1 in Group
II, and 3 in Group III. The doses and timing of those
immunosuppressive agents were described in more details in
the previous two papers [3, 15].
2.3. Deﬁnitionofaninfectiouscomplication
A bacterial, viral, or fungal infection was assumed to have
developed if clinical and/or laboratory evidence consistent
with acute infection developed. Such laboratory evidence
included relevant positive serologic markers and cultures
[16]. The criteria for sepsis deﬁned by Bone were applied
[17].
2.4. Virology
Serum HCV-ribonucleic acid was determined qualitatively
by applying the polymerase chain reaction according to
the protocols provided with a commercially available assay
(Amplicor HCV; Roche Molecular Systems, Pleasanton,
Calif, USA).
2.5. Tissuetyping
Serologic tissue typing for HLA-A, B (Bw), C, DR, and DQ
for class I and II loci was undertaken in all recipients.
2.6. Flowcytometry
We used peripheral blood mononuclear cells (PBMCs)
in all recipients. Sample analysis was always performed
within 24 hours after sampling. Since the numbers of
CD8+ T cells decreased often postoperatively to lower
than 10% of lymphocytes, we had to analyze CD8+ T
cell subsets with low numbers of events, and consequently
always performed at least duplicate assays of the same
sample. Cell staining was undertaken using monoclonal
antibodies as previously reported [3]. The monoclonal
antibodies used to stain cell surface antigens were as
follows: allophycocyanin (Coulter Immunotech, Miami, FL,
USA) or PC-5 (Coulter Immunotech, Marseilles, France)-
conjugated anti-CD4 or CD8, ﬂuorescein isothiocyanate-
conjugated anti-CD45RO (Nichirei, Tokyo, Japan), TC-
conjugated anti-CD45RA (Caltag Laboratories, Burlingame,
Calif, USA), phycoerythrin-conjugated anti-CD3 (Coulter
Immunotech, Miami, FL, USA), ﬂuorescein isothiocyanate-
conjugated anti-CD19 (Coulter Immunotech, Marseilles,
France), the phycoerythrin-conjugated anti-human CCR7
(DakoCytomation, Kyoto, Japan), phycoerythrin-conjugated
anti-CD27 (Coulter Immunotech, Marseilles, France), and
ﬂuorescein isothiocyanate-conjugated anti-CD28 (Nichirei,
Tokyo, Japan).
2.6.1. Flowcytometricdetectionofcytokineproduction
andintracellularstainingforperforin
Flow cytometric measurement of cytokine production was
performed as described previously [3]. Cells were stimulatedShinji Uemoto et al. 3
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Figure 1: Dendrogram of hierarchical clustering.
with a mixture of PMA (25ng/mL, Sigma-Aldrich Chemical
Co., MO, USA) and ionomycin (1μg/mL, Sigma-Aldrich)
with the Golgi inhibitor brefeldin A (10μg/mL, Sigma-
Aldrich). We measured intracellular perforin in CD8+ cells
without previous stimulation. The perforin analysis was
performed according to the previously reported method
[3, 18].
2.7. Discriminationofﬁrstphase(1st)and
secondphase(2nd)afterLDLT
The posttransplant period after LDLT was divided into two
phases.The1stphaseisthe24-hourperiodimmediatelyafter
graft reperfusion (before Tac administration) and the 2nd
phase is the period after the administration of Tac and other
immunosuppressants. The upregulation of eﬀector T cells in
the1stphaseismainlyduetoavigorousalloreactiveresponse
to alloantigen from the donor graft, whereas that in the 2nd
phase occurs predominantly as a result of infectious agents.
2.8. Statisticalanalysis
We undertook a hierarchical cluster analysis [19] using JMP
5 (SAS Institute Inc., Cary, NC, USA) to identify clusters of
recipients having similar distributions of naive-, CM-, EM-,
and eﬀector T cells. Hierarchical clustering produced a series
of partitions of the data. The ﬁrst consists of single-patient
clusters, and the last consists of a single group containing
all individuals. At each stage, the methods fuse groups of
individuals, which are most similar. We chose three as an
optimal number of clusters based on subjective expertise, as
shown in the dendrogram of Figure 1.
The posttransplant immune status was evaluated accord-
ing to the following measure and its graphical form.
2.8.1. %differenceasthemeasure
To quantify changes in posttransplant alloreactive responses,
the proportion of CD8+ T cell subsets immediately before
LDLT (pretransplant immune status) was subtracted from
the proportion at various times after LDLT and is expressed
as % diﬀerence. This value reﬂects current immune status
after LDLT. Similarly, the % diﬀerence was calculated for
other variables such as IFN-γ, perforin, and CD27−CD28−
subsets. By this assay, it is possible to compare posttransplant
immune status between heterogeneous recipients.
2.8.2. Scatterplotasthegraphicalform
The deviation points of the CD8+ Ed i ﬀerence (Y axis)
from pretransplant values were plotted as a function of the
proportion of pre-existing CD8+ eﬀector T cells (X axis) for
each recipient. The 0 point in the Y axis indicates immune
status just before LDLT. The slope of the correlation line was
unity from the deﬁnition in all heterogeneous recipients.
The relation between continuous variables was investi-
gated by means of Pearson’s correlation coeﬃcient. Com-
parisons for continuous variables between groups were
undertaken by applying Student’s t-test and analysis of
variance. Comparisons for proportions between groups were
undertaken using Fisher’s exact test or chi-square test. All
statistical tests were 2-tailed. Statistical signiﬁcance was
deﬁned as P<. 05.
3. RESULTS
3.1. Hierarchicalclusteringaccordingtopreoperative
CD8+CD45isoformproﬁles
The ABO-identical and -compatible recipients (n = 92)
were divided into three groups according to hierarchical
clusteringbasedonpretransplantCD3+CD8+CD45isoforms
(Table I(a)). The median age of all the recipients was 53 years
(range: 19 to 67 years). The age of Group I was signiﬁcantly
younger than in Groups II and III. The pretransplant naive T
cell population was most abundant in Group I, EM T cells
were the most prevalent in Group II, and eﬀector T cells4 Clinical and Developmental Immunology
Table 1: Hierarchical clustering in 3 Groups.
(a)
Group n Age (y) %N a i v e %C M %E M %E ﬀector %
Lymphocytes∗ %C D 4 † %C D 8 †
Tc e l l s Tc e l l s Tc e l l s Tc e l l s
I 31 47 ±11 53.44 ±10.42 7.56 ±4.19 7.01 ±5.53 17.51 ±7.76 19.81 ±10.34 47.05 ±15.50 20.83 ±10.26
II 33 53 ±8 20.80 ±10.99 11.88 ±6.04 20.24 ±7.21 24.25 ±11.66 21.22 ±10.24 46.86 ±11.54 19.71 ±9.17
III 28 53 ±12 21.22 ±10.52 5.88 ±3.43 7.33 ±4.59 48.36 ±12.77 20.76 ±11.56 42.89 ±12.75 21.74 ±7.47
(b)
Variance
All P‡ .0501 <.0001 <.0001 <.0001 <.0001 .8693 .4087 .6845
Iv e r s u sI I P‡ .0223 <.0001 .0016 <.0001 .0089 .5910 .9567 .6480
Iv e r s u sI I I P‡ .0647 <.0001 .1001 .9287 <.0001 .7446 .2681 .7004
II versus III P‡ .9133 .8840 <.0001 <.0001 <.0001 .8735 .2066 .3534
(c)
Group I Group II Group III P
Recipient (male/female) 31 (18/13) 33 (23/10) 28 (15/13) .4049‡
Original liver disease — — — .1456‡
Nonviral 14 9 6 —
HBV 6 12 6 —
H C V 1 11 31 6 —
MELD 17 ±10 16 ±91 4 ±7 .5460§
HLA mismatch (0–2/>3) 17/13 16/15 7/21 .0347‡
CMV status: R+ (D+/R−) 26/29 (3/29) 25/31 (6/31) 23/26 (2/26) .5504 (0.3971)‡
EBV status: R+ (D+/R−) 24/29 (3/29) 28/30 (2/30) 23/27 (3/27) .4442 (0.8232)‡
Operation proﬁle
GWBR 1.13 ±0.26 1.33 ±1.07 1.16 ±0.27 .4422§
Ischemic time (min) Cold 104 ±74 115 ±62 144 ±92 .1276§
Warm 51 ±24 60 ±48 54 ±17 .5502§
Blood loss (g) 7647 ±12227 7761 ±10135 9084 ±11086 .8615§
Blood loss/BW 0.14 ±0.28 0.13 ±0.17 0.15 ±0.19 .8719§
Viral status: R+; recipient with preoperative positive serology, D+/R−; donor-positive and recipient-negative status, ∗% of peripheral blood mononuclear
cells; †%o fl y m p h o c y t e s ;‡Categorical variables were compared using Fisher’s exact test or chi-squared test; §Continuous variables between groups were
compared using Student’s t-test or ANOVA. Values are expressed as mean ±SD.
were the most abundant in Group III. Accordingly, Groups
I, II, and III were designated as naive-, EM-, and eﬀector-
cell dominant, respectively. The proportion of eﬀector T
cell increased signiﬁcantly and progressively increased from
Group I to Group III (Table I(b)). The CM T cell proportion
was signiﬁcantly higher in Group II than in Groups I and III.
Table I(c)showsproﬁlesoftherecipientsandthesurgery.
One Group II recipient had both hepatitis B virus (HBV)
and HCV infection and was classiﬁed into both the HBV
and HCV groups, so in total 63 recipients were infected
with HBV (n = 24) or HCV (n = 40), while 29 were not
infected with either virus (nonviral). The primary diseases of
the nonviral recipients were biliary atresia (n = 3), primary
biliary cirrhosis (n = 10), fulminant hepatic failure (n =
6), primary sclerosing cholangitis (n = 3), alcoholic liver
cirrhosis (n = 2), liver cirrhosis (unclear) (n = 1), polycystic
disease (n = 1), Caroli disease (n = 1), hepatocellular
carcinoma (n = 1), and autoimmune hepatitis (n = 1).
The clinical status of the 3 groups did not signiﬁcantly
diﬀer according to the model for end-stage liver disease
score [20] and operation proﬁles. The HLA mismatched
loci (>3) were statistically high in Group III rather than
in Groups I and II. The possibility that a high number
of HLA mismatches may be, at least partly, related to the
development of posttransplant infection, cannot be denied.
In the pretransplant Cytomegalovirus (CMV) and EBV
statuses, CMV-positive recipients were 90% of Group I, 81%
of Group II, and 88% of Group III; EBV-positive recipientsShinji Uemoto et al. 5
were 83% of Group I, 93% of Group II, and 85% of Group
III. In donors, 71% of Group I, 91% of Group II, and 92% of
Group III were CMV positive, and 64% of Group I, 81% of
GroupII,and58%ofGroupIIIwereEBVpositive.Therewas
no signiﬁcant diﬀerence in the frequency. The frequencies
of donor-positive and recipient-negative statuses were also
similar among the three groups, as shown in Table I(c). Also,
there was not diﬀerent in the operation proﬁles 3 groups.
3.2. Changesinthe%differenceofCD8+ Tcellsubsets
andthescatterplotafterLDLTin3groups
Figure 2(a) shows the additional changes of CD8+ Tc e l l
subsets burden by LDLT in comparison with the pretrans-
plant immune status, which is expressed as the % diﬀerence,
after LDLT in 3 groups. In 3 groups, the % E diﬀerence was
promptly upregulated maximally at 6 hours after graft reper-
fusion and then decreased to near or below the pretransplant
levels after Tac administration. The maximum levels of
upregulationat6hourswereconsiderablyhigherinGroupsI
andIIthaninGroupIII.InGroupI,afterTacadministration
the % E diﬀerence increased from day 26 to the maximum at
day 40 and then remained at the same levels throughout the
posttransplant period, accompanied by similar upregulation
of % EM diﬀerence. The % naive diﬀerence correlated
signiﬁcantly (r =− 0.741, P<. 0001) negatively with the
%Ed i ﬀerence. The % CM diﬀerence remained unchanged
after LDLT. In Group II, the % E diﬀerence increased to
several % at day 30 but remained at near the baseline in the
other period, showing negative (r =− 0.559, P<. 0001) %
diﬀerence of naive and eﬀector T cells. The % CM diﬀerence
remained unchanged after LDLT. By contrast, in Group III
the % E diﬀerence was greatly downregulated to far below
pretransplant levels and then remained at the same levels
for a prolonged period. The % EM diﬀerence was increased
to approximately 10% over the pretransplant levels at day
5 0 .T h e%n a i v ed i ﬀerence signiﬁcantly (r =− 0.803, P<
.0001) correlated negatively with % E diﬀerence. The % CM
diﬀerence remained unchanged around the baseline.
Figure 2(b) shows the scatter plot points for the post-
transplant CD8+ %Ed i ﬀerence in relation to the pre-
transplant proportion of % eﬀector T cells for each of
the heterogeneous recipients. The range of the % CD8+
eﬀector T cells on the baseline, equivalent to pre-existing
values before LDLT, progressively increased from Group I,
through Group II, to Group III recipients. In Groups I
and II, the scatter plot shows a clear left shift together
with many upregulation points and few downregulation
points of % E diﬀerence from the baseline. In Group III,
in sharp contrast, the scatter plot shows a clear right shift
together with signiﬁcantly many downregulation points and
few upregulation points from the baseline. In addition, the
greater the right shift, the more the % E diﬀerence was
downregulated. More importantly, the deviation of the % E
diﬀerence was relatively similar in Groups I and II, although
pre-existing eﬀector T cell proportion was slightly higher
in Group II than in Group I. In contrast, in Group III the
deviation of % E diﬀerence was greatly downregulated while
the pre-existing eﬀector T cells were the highest.
From the results mentioned above, it is likely that in
Groups I and II the CD8+ T cells have the full capacity
to eﬃciently induce cytotoxic activity in response to invad-
ing pathogen (so-called hyperresponsive), as evidenced by
upregulation of eﬀector T cells and IFN-γ expression. By
contrast, in Group III the CD8+ T cells cannot induce
cytotoxic T lymphocyte (CTL) cytotoxicity by their down-
regulation (hyporesponsive or exhausted). It seems likely
that immune status after LDLT is determined by pre-existing
levels of eﬀector T cells.
3.3. Longitudinallyprolongedfollow-upofthe%E
differenceandscatterplotinGroupIIIrecipient
Figure 3 shows the additional changes in the % diﬀerence
of CD8+ T cell subsets burden by LDLT in comparison
with the pretransplant immune status at various times in a
55-year-old female recipient who underwent LDLT to treat
HCV-related liver cirrhosis and hepatocellular carcinoma.
Her extant CD8+ naive T cell proportion was only 13.3%
(Group III). The CD8+ %Ed i ﬀerence was signiﬁcantly
downregulated after cyclosporine administration and then
remained at the lowest levels far from the baseline until
day 220 (left). By day 12, this patient developed acute
cellular rejection, infection, and aspartate aminotransferase
was elevated (“A” zone of lowest levels). Between days 25–
50, acute cellularrejection and elevated serum transaminases
persisted (“B” zone). The CD8+ %Ed i ﬀerence gradually
increased at day 150. Around day 200, the % E diﬀerence
transiently downregulated with highly elevated aspartate
aminotransferase, and then the patient was discharged on
day 247 when the % E diﬀerence reached baseline. The
%d i ﬀerences of EM T cells in CD8+ Tc e l l sw e r ea l w a y s
above baseline. The scatter plot (right) shows that the % E
diﬀerence progressively increased from zone A to zone C in
her clinical course.
3.4. Frequenciesofposttransplantinfection,rejection,
life-threateninginfectiouscomplication(LTC),and
hospitalmortalityafterLDLTin3groups
Table 2 shows the frequencies of posttransplant infection,
rejection, LTC, and hospital mortality after LDLT in 3 groups
of nonviral-, HCV-, and HCV-related recipients.
3.4.1. Infection
The postoperative infection rates progressively increased
from Group I to III recipients. The bacterial infection rate
progressively increased from Group I to III recipients. The
frequencies of infection were signiﬁcantly higher in Group
III than in Groups I and II. Bacterial infections were caused
mostly by Staphylococci, Enterococci, or Pseudomonas species.
The fungal infection rates were the highest (21.4%) in
Group III than in Groups I (6.5%) or II (6.1%). Moreover,
logistic regression analysis adjusted for age, gender, and
primary disease showed that the frequency of infection was
signiﬁcantly greater in Group III than Group I (odds ratio:
5.69, 95% CI: 1.70–19.1, P = .005) or Group II (odds6 Clinical and Developmental Immunology
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Figure 2: Changes in the % diﬀerence of the CD8+ T cell subsets (a) and the scatter plot (b) after LDLT in 31 Group I, 33 Group II, and 28
Group III recipients. The % diﬀerence was expressed by subtracting the proportion of CD8+ T cell subsets immediately before LDLT from
the proportion at various times after LDLT. In the scatter plot, the deviation points of the % E diﬀerence from pretransplant values were
plotted as a function of the proportion of pre-existing CD8+ eﬀector T cells for each recipient. N, naive T cells; E, eﬀector T cells; CM,central
memory T cells; EM, eﬀector memory T cells; Tac, tacrolimus.
ratio: 3.53, 95% CI: 1.15–10.9, P = .028). The frequency of
bacterial infection was signiﬁcantly greater in Group III than
Group I (odds ratio: 5.70, 95% CI: 1.41–23.0, P = .015).
The infection frequencies did not diﬀer among nonviral-,
HBV-, and HCV-related recipients. The overall incidence
of Cytomegaloviral diseases after LDLT was 30.4% with
being more frequent in Group III (46.4%) than in Groups
I (25.8%) and II (21.2%). LTC such as septic shock, adult
respiratory distress syndrome, and hepatic necrosis occurred
in 6 (14.7%) of 92 recipients (2 in nonviral, 1 in HBV, and
4 in HCV). The frequencies of LTC were higher in Group III
(10.7%) than in Group I (3.2%) and Group II (6.1%).
3.4.2. Rejection
The frequencies of acute cellular rejection were 23 (25%)
of 92 recipients with being more frequent in Group II
(33.3%)andGroupIII(28.6%)thaninGroupI(12.9%).The
frequency of rejection was signiﬁcantly greater in Group II
thanGroupI(oddsratio:4.50,95%CI:1.15–17.5,P = .030).
3.4.3. Hospitalmortalityrate
The numbers of hospital death were 7 (7.6%) of 92
recipients. The hospital mortality rate was higher in Group
II (9.1%) and Group III (10.7%) than in Group I (3.2%).
3.5. Changesinposttransplantimmunestatusin
representativeofGroupsI,II,andIII
Figure 4 shows the distribution of CD8+ T cell subsets by
ﬂow cytometry (a) and changes in the proportion of CD8+ T
cell subsets (b) as well as IFN-γ, perforin, and CD27−CD28−
subsets(c)afterLDLTinarepresentativeofGroupIrecipient
(53-year-old female) undergoing LDLT to treat HCV-related
liver cirrhosis. The proportion of eﬀector T cells increased
only slightly during 3–6 hours after graft reperfusion andShinji Uemoto et al. 7
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Figure 3: Changes in % diﬀerence in CD8+ naive, CM, EM, and eﬀector T cells after LDLT in a 55-year-old female recipient. Right, scatter
plot between % E diﬀerence and % eﬀe c t o rTc e l lp r o p o r t i o n .A ,p e r i o da s s o c i a t e dw i t ha c u t e cellular rejection, infection and liver damage.
B, period associated with acute cellular rejection and aspartate aminotransferase elevation. C, aspartate aminotransferase elevation. White
circles denote naive (N), black circles denote eﬀector (E), white triangles denote central memory (CM), black triangles denote eﬀector
memory (EM), Pre, pre-LDLT; CsA, cyclosporine A; Tac, tacrolimus; the number below black circles in right ﬁgure, postoperative days.
Table 2: Frequencies of Posttransplant Infection, Complication and Mortality in 3 Groups.
Group Primary disease Total Infection Rejection LTC∗ Hospital death
Bacteria Virus Fungus
nn (%) n (%) n (%) n (%) n (%) n (%) n (%)
I
Nonviral 14 5 2 5 2 4 1 1
HBV 6 0 0 0 0 0 0 0
H C V 1 1 423000 0
Total 31 9 (29.0) 4 (12.9) 8 (25.8) 2 (6.5) 4 (12.9) 1 (3.2) 1 (3.2)
II
N o n v i r a l 9 542020 0
HBV 12† 3† 3† 2† 05 1 † 1†
HCV 13† 4† 3† 4† 24 2 † 3†
Total 33 11 (33.3) 9 (27.3) 7 (21.2) 2 (6.1) 11 (33.3) 2 (6.1) 3 (9.1)
III
N o n v i r a l 6 545321 1
HBV 6 4 2 3 0 1 0 0
H C V 1 6 955352 2
Total 28 18 (64.3) 11(39.3) 13 (46.4) 6 (21.4) 8 (28.6) 3 (10.7) 3 (10.7)
All P‡ — .0117 .0690 .0812 .0985 .1472 .5038 .5131
Iv e r s u sI I P§ — .7908 .2168 .7711 >.999 .0773 >.999 .6136
Iv e r s u sI I I P§ — .0092 .0346 .1124 .1337 .1974 .3373 .3373
II versus III P§ — .0215 .4141 .0533 .1272 .7847 .6533 >.999
∗ LTC, Life-threatening infectious complication; †one recipient had HBV- and HCV-infection; ‡P-values are based on chi-square test; §P-values are based on
Fisher’s exact test.
then decreased by Tac administered from postoperative 24
hours. The proportion of EM and eﬀector T cells increased
from day 19, peaking at day 30. The proportion of IFN-
γ, perforin, and CD27−CD28− subsets remained relatively
unchanged by day 19 and then increased to maximal levels at
day 30 (c). On day 27 after LDLT, Doppler ultrasonography
detected interrupted ﬂow in the hepatic artery. Because
serum asparatate aminotransferase was minimally increased
(about 50IU/L), anticoagulant therapy was applied to the
recipient under close observation. During this period, this
recipient developed infection, CMV at day 34, Enterobacter
cloacae in blood at day 28, Enterococcus in catheter at day
50, Staphylococcus maltophilia, and Enterococcus faecalis in
pharynx at day 61, Coagulase negative Staphylococcus in
blood at day 75, and Candida in urine at day 61. The his-
tological examination of a liver biopsy specimen performed8 Clinical and Developmental Immunology
at day 35 showed pericentral venous hemorrhage. Doppler
ultrasonography on day 41 showed that arterial ﬂow had
recovered. The % E diﬀerence was slightly downregulated
on day 61 in parallel with recirculation of the hepatic artery
ﬂow and amelioration of infection. These ﬁndings indicate
that changes in the % E diﬀerence are closely related to the
incidence of posttransplant infection.
Figure 5showstheadditionalchangesinthe%diﬀerence
of CD8+ T cell subsets as well as IFN-γ, perforin, and
CD27−CD28− subsets burden by LDLT in comparison with
the pretransplant immune status at various times in the
same recipient of Figure 4.T h e%Ed i ﬀerence increased
only slightly during 3–6 hours and then decreased after
Tac administration, further increasing again from day 19,
along with an increase in % EM diﬀerence (a). The % naive
diﬀerence greatly downregulated from day 30, while the %
CM diﬀerence remained unchanged at slightly below the
baseline throughout the post-LDLT period. On the other
hand,the%diﬀerenceofIFN-γ,perforin,andCD27−CD28−
subsets increased slightly during the 3–12 hours period,
decreased to pretransplant levels after Tac administration
and then began to increase from day 19, peaking at day
30, simultaneously with the development of infection (b).
The low (c) ﬁgure shows the scatter plot of posttransplant
deviation of the % E diﬀerence from the pre-existing eﬀector
T cell proportion for this recipient. All points were situated
above the baseline. The upregulation of % E diﬀerence
immediately after graft reperfusion (1st phase) was less than
10% above the baseline. With the onset of severe infection
following hepatic artery ﬂow interruption, the scatter plot
points were located at the highest and furthest point from
zero (2nd phase). These results indicate that the deviation
of the % E diﬀerence is greatest when there is a vigorous
response to infection.
Figure 6(a) shows additional changes in the % diﬀerence
of CD8+ T cell subsets as well as IFN-γ, perforin, and
CD27−CD28− subsets burden after LDLT in comparison
with the pretransplant immune status at various times
and the scatter plots showing the relationship between the
%Ed i ﬀerence and the proportion of CD8+ eﬀector T
cells in a representative of Group II recipient (62-year-
old male) undergoing LDLT to treat HCV-related cirrhosis
and hepatocellular carcinoma. The % E diﬀerence increased
greatly in the 3–6 hours period, and then decreased to
the baseline after Tac administration. The % diﬀerence of
the other subsets remained unchanged at slightly below
the baseline throughout (left). The % diﬀerence of IFN-
γ, perforin, and CD27−CD28− subsets increased greatly
from 3–12 hours but decreased to the baseline after Tac
administration (middle). All the scatter plots were above
the baseline, showing the highest % diﬀerence during the
vigorous alloreactive response in the 1–12 hours period after
graft reperfusion (1st phase), before returning to near the
baseline after Tac administration (2nd phase) (right). This
recipient was discharged uneventfully at day 45 without
development of infection.
Figure 6(b) shows changes in the % diﬀerence in CD8+
T cell subsets as well as IFN-γ, perforin, and CD27−CD28−
subsets after LDLT in a representative of Group III recipient
(60-year-old male) undergoing LDLT to treat HBV-related
cirrhosis and hepatocellular carcinoma. The % E diﬀerence
decreased profoundly to −30% after Tac administration and
remained at this level until day 68. The % naive T cell
diﬀerence increased slightly, but the other subsets remained
at the baseline (left). Corresponding to the decrease of the
%Ed i ﬀerence, the % diﬀerence of IFN-γ, perforin, and
CD27−CD28− subsets was similarly strongly downregulated
after Tac administration but increased from day 24 (middle).
All scatter plots were situated below the baseline (right),
between 0 and –30% in the period immediately after graft
reperfusion (1st phase) but showed strong further downreg-
ulation also after Tac administration (2nd phase). During
operation, the hepatic artery anastomosis was impossible
because of the vascular anomaly. A moderate elevation of
serum aspartate aminotransferase and C-reactive protein
continued from day 19. Athelectasis of the lungs developed
at day 15 and infection occurred from day 10; Enterobacter
cloacae and Pseudomonas aeruginosa presented in urine at
day 10 and 53; andCMV atday 32. Atday19, thehistological
examination of liver biopsy specimen showed cholestasis
and cholangitis. After discharge at postoperative day 81, this
recipient had to be very often hospitalized due to recurrence
of severe infection combined with septic shock, possibly
secondary to prolonged downregulation of % E diﬀerence.
3.6. Changesinthe%IFN-γ differenceafterLDLT
Figure 7 shows changes in the % IFN-γ diﬀerence after
LDLT in 3 groups. Immediately after graft reperfusion, the
%I F N - γ diﬀerence upregulated at 3–6 hours progressively
from Group I to Group III recipients. By contrast, after
Tac administration, conversely, the % IFN-γ diﬀerence
downregulated progressively from Group I to III recipients.
The period to restore to pretransplant value was the longest
in Group III rather than in Groups I and II.
4. DISCUSSION
4.1. Betterevaluationofposttransplantimmune
statusbythe%differenceratherthanby
theproportion
There were markedly diﬀerent phenotypes and functions of
TcellsbeforeandafterLDLTamongthemanyheterogeneous
recipients. The posttransplant immune status cannot be
clearlyestimatedbyup-ordownregulationoftheproportion
of T cell subsets, cytokines, and perforin. From the analysis
of our extensive data bank, it has already been found that,
in order to compare the posttransplant immune status in
many recipients, it is particularly useful to estimate the
magnitude of the additional immunological load burden by
liver transplantation in comparison with the pretransplant
immune status, which is expressed as the % diﬀerence. The
following issues have been clariﬁed by this assay: (1) post-
transplant changes in phenotypic and functional properties
of CD4+ and CD8+ T cells, albeit in a diﬀerent period, can
be almost restored to the pretransplant pattern; therefore,
the pretransplant value can be chosen as the starting timeShinji Uemoto et al. 9
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Figure 4: Changes in CD45 isoforms of CD8+ Tc e l l s ,C D 2 7 −CD28− subsets, IFN-γ producing cells and perforin expression after LDLT in
a 53-year-old, female recipient who underwent LDLT to treat HCV-related liver cirrhosis. In (a), ﬂow cytometry, using peripheral blood
nuclear cells (PBNCs) the lymphocytes were stained with monoclonal antibodies to CD45RO and CCR7. The representative dot plots
show double-staining for CD8+CCR7/CD45RO on gated lymphocytes (i), which identiﬁed 4 subsets of CD8+: naive (CD45RO−CCR7+),
central memory (CD45RO+CCR7+), eﬀector memory (CD45RO+CCR7−), and eﬀector T cells (CD45RO−CCR7−). Other dot plots show
double-staining for CD27/CD28 on gated CD8+ T cells (ii), CCR7/IFN-γ on gated CD8+CD45RA+ cells (iii), perforin/CCR7 on gated
CD8+CD45RO− cells (iv). Cells in quadrants are presented as ratios (%). Right low (c), proportions of perforin and IFN-γ expression are
expressed as ratios (%) of CD8+ Tc e l l s .P r e ,p r e - L D L T ;T a c ,t a c r o l i m u s .( b )N ,n a i v eTc e l l s ;E ,e ﬀector T cells; CM, central memory T cells;
EM, eﬀector memory T cells; and HAI, hepatic artery ﬂow interruption. (c) IFN-γ, interferon-gamma; and CD27−CD28−,C D 2 7 −CD28−
subsets.10 Clinical and Developmental Immunology
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Figure 5: Changes in % diﬀerence in CD8+ naive, CM, EM, and eﬀector T cells, as well as IFN-γ, perforin, and CD27−CD28− subsets after
LDLT in same recipient shown in Figure 4. Low (c), scatter plot between % E diﬀerence and % eﬀector T cell proportion. 1st phase is the
period before Tac administration. 2nd phase is the period after Tac administration. Pre, pre-LDLT; Tac, tacrolimus; the number above black
circles in (c) ﬁgure, postoperative days. (a) N, naive T cells; E, eﬀector T cells; CM, central memory T cells; and EM, eﬀector memory T cells.
(b) IFN-γ, interferon-gamma; and CD27−CD28−,C D 2 7 −CD28− subsets. (c) HAI, hepatic artery ﬂow interruption.
point; (2) in order to compare the posttransplant immune
status among many recipients, their immune status, even
though on a small scale, can be exactly estimated by the
changes in the % diﬀerence rather than the proportion;
and (3) CD8+ CTL generation varied markedly after LDLT
in many recipients. Evaluation of the % diﬀerence was
closely related to posttransplant infection and the recipient’s
survival probability. From these results, it is possible to
compare the enhanced immune status induced after LDLT
among heterogeneous recipients.
4.2. DistinctimmuneresponseafterLDLTin3groups
Antigen-primed CD8+ memory T cells can be distinguished
by CCR7 and CD45RA expression into distinct long-
lived CCR7+CD45RA− “central memory,” CCR7−CD45RO+
“eﬀector memory,” and CCR7−CD45RA+ “eﬀector subsets”
[21]. In Groups I and II, % diﬀerence of CD8+ CM
or EM T cells remained at baseline or slightly above
throughout the posttransplant period. However, the % E
diﬀerence signiﬁcantly upregulated after LDLT and new
invading pathogens were cleared. In Group III, in sharp
contrast, the % E diﬀerence after LDLT was remarkably
downregulated in Group III and accompanied by obvious
decreases in IFN-γ-producing cells, perforin expression, and
CD27−CD28− subsets. In those recipients, pathogens could
not eﬃciently be cleared during downregulation of the %
Ed i ﬀerence, leading to a high posttransplant incidence of
critical infectious complications. These results indicate that
the pre-existing memory subset population before LDLT
restricted such changes in CD8+ memory subsets after
LDLT in the 3 groups, indicating the so-called heterologous
immunity [1, 2].
A potentially important factor contributing to posttrans-
plantinfectiouscomplicationistheinabilityofCD8+ eﬀector
Tcellstocontrolinfection.Theclearanceofviruses,bacteria,Shinji Uemoto et al. 11
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Figure 6: (a) Changes in % diﬀerence in CD8+ naive, CM, EM, and eﬀector T cells, as well as IFN-γ, perforin, and CD27−CD28− subsets
in a 62-year-old male recipient undergoing LDLT to treat HCV-related liver cirrhosis and hepatocellular carcinoma. Right, scatter plot
between % E diﬀerence and % eﬀector T cell proportion. 1st phase is the period before Tac administration. 2nd phase is the period after
Tac administration. Pre, pre-LDLT; Tac, tacrolimus; the number above black circles in right ﬁgure, postoperative days. Left ﬁgure: N, naive
Tc e l l s ;E ,e ﬀector T cells; CM, central memory T cells; and EM, eﬀector memory T cells. Middle ﬁgure: IFN-γ, interferon-gamma; and
CD27−CD28−,C D 2 7 −CD28− subsets. (b) Posttransplant changes in % diﬀerence in CD8+ T cell subsets as well as IFN-γ, perforin, and
CD27−CD28− subsets in a 60-year male recipient undergoing to treat HBV-related liver cirrhosis and hepatocellular carcinoma. Right,
Scatter plot between % E diﬀerence and % eﬀector T cell proportion. 1st phase is the period before Tac administration. 2nd phase is the
period after Tac administration. Pre, pre-LDLT; Tac, tacrolimus; HAI, hepatic artery ﬂow interruption; Bx, biopsy; the number above black
circles in right ﬁgure, postoperative days.
and fungus by the immune response is thought to require
the destruction of infected cells by CTLs via perforin. The
perforin pathway involves granule exocytosis and might be
the most eﬀective in vivo, at least, in terms of controlling
microbial infections [22, 23]. The memory CD8+ Tc e l l s
in Groups I and II could acquire cytotoxic activity very
rapidly and may have signiﬁcantly contributed to even the
earliest control of viral replication and bacteria by killing
infected cells. Thereafter, lytic activity would have gradually
decreased as the infection was cleared, as previously reported
[24]. In contrast, CTL cytotoxicity brought about by per-
forin expression was greatly impaired in severely infected
Group III recipients. A lag time may exist between the
downregulation of % E diﬀerence and the restoration of % E
diﬀerence associated with the ability to clear these invading
pathogens. If the great downregulation continued for a
prolonged period, it rendered transplanted recipients highly
susceptible to infection and was refractory to pathogen
clearance. Viral and bacterial pathogens in those recipients
might easily be activated and continuously retained during
the prolonged lag time. The clear downregulation of % E
diﬀerence might be equivalent to the functional exhaustion
proposed by Wherry et al [25]. Thus, changes in the %
Ed i ﬀerence after LDLT can be mainly classiﬁed into two
groupsofCD8+ Tcellswitheitherahighoralowproportion
of pre-existing eﬀector T cells. The alloimmunity of Groups
I and II was associated with upregulation of CTL cytotoxicity
in response to infection-hyperresponsive, whereas Group
III was accompanied by downregulation of cytotoxicity
hyporesponsive.
4.3. ProposedroleofTacinducingthedownregulation
of%Edifference
As factors contributing to downregulation of eﬀector T cells,
various factors such as inappropriate immunosuppression,12 Clinical and Developmental Immunology
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Figure 7: Changes in the % IFN-γ diﬀerence after LDLT in 3
groups. ∗P-value at day 2 is based on analysis of variance: all, .0161.
P-values between 3 groups are based on Student’s t-test: Group I
versus II, .0248; Group I versus III, .0133; and Group II versus III,
.3058.
infection, and rejection could be considered. Among them,
the Tac administration in Groups I and II suppressed a
vigorous immune response against alloantigens from the
transplanted allograft immediately after LDLT, as indicated
by normalization of the % E diﬀerence or scatter plot to
around baseline at posttransplant day 2, when the trough
reached to an appropriate level. In Group III, in contrast,
the % E diﬀerence was greatly downregulated after Tac
administration and took more prolonged time to restore to
pretransplant levels than in Groups I and II. The mechanism
is now unknown, but it seems likely that the CD8+ T
cells enriched with pre-existing high eﬀector T cell may
have the highest native impact to Tac administration. On
the other hand, in the experimental study, it has been
found that in the mice dominated by IFN-γ production
the carcineurin-inhibitor (Tac and cyclosporine A) therapy
eﬀectivelyinducedlong-termgraftsurvivalaftercardiacallo-
grafting, whereas in IFN-γ-deﬁcient mice the same therapy
showed only marginally prolonged graft survival, along with
resistance to carcineurin inhibitor [26, 27]. Accordingly, it
seems likely that in the eﬀector-dominant recipients the CTL
activity cannot eﬀectively respond to Tac therapy during
downregulation of IFN-γ production.
4.4. Posttransplantinfectionand
acutecellularrejection
The interrelationships between immunosuppression, infec-
tions, and allograft rejection are certainly highly complex
and incompletely understood [28]. In this study, most
of the acute cellular rejection occurred in the period of
downregulation of the % E diﬀerence but not at the time
of upregulation. This may be consistent with the facts that
the heterologous memory generated by bacterial and viral
antigens has been shown to be a barrier for transplantation
tolerance and is associated with increased rates of acute
rejection and impaired graft function [1, 2].
5. CONCLUSION
5.1. Novelperspective
The favorable outcome of LDLT is the prompt restoration of
the immune system to pretransplant status associated with
active immune regulation, as evidenced by maintaining a
%Ed i ﬀerence or scatter plot to around the baseline. The
naive-dominant recipients are uniformly highly sensitive to
pathogen clearance. Indeed, their CTLs were generated in
responsetoinfectionearlierandmorerapidlyinCD8+ naive-
dominant, than in either CD8+ EM- or eﬀector-dominant T
cells [24].
From the results mentioned above, preserving immunity
by minimizing immunosuppression might be one of the
most important challenges in posttransplant management
in Group III. The assay of % E diﬀerence or scatter plot is
simply practicable and can be used as a potentially useful
marker for posttransplant infectious complications. Firstly,
the classiﬁcation of naive-, EM-, and eﬀector-dominant
recipients is done according to pre-existing CD8+ Tc e l l
subsets. Second, if the recipient belongs to Group III, the
magnitude of downregulation of % E diﬀerence at the
posttransplant day 2 after Tac administration is determined.
At present, we are now working to determine whether
it is possible to tailor immunosuppression for high-risk
Group III recipients to improve their clinical outcomes. Such
consideration will open the door to novel and better targeted
therapies.
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